2015. The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells. Journal of Pharmaceutical Negative Results. 6, 1 (Jan. 2015), 7–10.